| Antigen-based testing but not real-time polymerase chain reaction correlates with severe acute respiratory syndrome coronavirus 2 viral culture A Pekosz, V Parvu, M Li, JC Andrews, YC Manabe, S Kodsi, DS Gary, ... Clinical Infectious Diseases 73 (9), e2861-e2866, 2021 | 246 | 2021 |
| The Onclarity human papillomavirus trial: design, methods, and baseline results MH Stoler, TC Wright Jr, V Parvu, L Vaughan, K Yanson, K Eckert, ... Gynecologic oncology 149 (3), 498-505, 2018 | 90 | 2018 |
| Factors that influence the reported sensitivity of rapid antigen testing for SARS-CoV-2 V Parvu, DS Gary, J Mann, YC Lin, D Mills, L Cooper, JC Andrews, ... Frontiers in microbiology 12, 714242, 2021 | 71 | 2021 |
| Safety and efficacy of insulin therapy delivered via a 4mm pen needle in obese patients with diabetes RM Bergenstal, ES Strock, D Peremislov, MA Gibney, V Parvu, LJ Hirsch Mayo Clinic Proceedings 90 (3), 329-338, 2015 | 69 | 2015 |
| Stratified risk of high-grade cervical disease using onclarity HPV extended genotyping in women,≥ 25 years of age, with NILM cytology MH Stoler, TC Wright Jr, V Parvu, K Yanson, CK Cooper, J Andrews Gynecologic oncology 153 (1), 26-33, 2019 | 62 | 2019 |
| Risk detection for high-grade cervical disease using Onclarity HPV extended genotyping in women,≥ 21 years of age, with ASC-US or LSIL cytology TC Wright Jr, MH Stoler, V Parvu, K Yanson, C Cooper, J Andrews Gynecologic oncology 154 (2), 360-367, 2019 | 59 | 2019 |
| Antigen-based testing but not real-time PCR correlates with SARS-CoV-2 virus culture A Pekosz, CK Cooper, V Parvu, M Li, JC Andrews, YC Manabe, S Kodsi, ... MedRxiv, 2020.10. 02.20205708, 2020 | 57 | 2020 |
| HPV infections and cytologic abnormalities in vaccinated women 21–34 years of age: Results from the baseline phase of the Onclarity trial TC Wright Jr, V Parvu, MH Stoler, S Kodsi, K Eckert, K Yanson, ... Gynecologic oncology 153 (2), 259-265, 2019 | 45 | 2019 |
| Risk of cervical intraepithelial neoplasia 2 or worse by cytology, human papillomavirus 16/18, and colposcopy impression: a systematic review and meta-analysis MI Silver, J Andrews, CK Cooper, JC Gage, MA Gold, MJ Khan, ... Obstetrics & Gynecology 132 (3), 725-735, 2018 | 45 | 2018 |
| Bayesian analysis of baseline risk of CIN2 and≥ CIN3 by HPV genotype in a European referral cohort J Bonde, F Bottari, V Parvu, H Pedersen, K Yanson, AD Iacobone, S Kodsi, ... International Journal of Cancer 145 (4), 1033-1041, 2019 | 37 | 2019 |
| Detection of cervical neoplasia by human papillomavirus testing in an atypical squamous cells-undetermined significance population: results of the Becton Dickinson Onclarity trial TC Wright Jr, MH Stoler, V Parvu, K Yanson, K Eckert, S Kodsi, ... American journal of clinical pathology 151 (1), 53-62, 2019 | 36 | 2019 |
| HPV testing with 16, 18, and 45 genotyping stratifies cancer risk for women with normal cytology: data from the baseline phase of the Onclarity trial MH Stoler, TC Wright Jr, V Parvu, K Yanson, K Eckert, S Kodsi, C Cooper American journal of clinical pathology 151 (4), 433-442, 2019 | 31 | 2019 |
| Evaluation of a new safety peripheral IV catheter designed to reduce mucocutaneous blood exposure R Onia, I Eshun-Wilson, C Arce, C Ellis, V Parvu, D Hassman, ... Current medical research and opinion 27 (7), 1339-1346, 2011 | 17 | 2011 |
| Simulated evaluation of a non-Luer safety connector system for use in neuraxial procedures R Onia, Y Wu, V Parvu, I Eshun-Wilson, K Kassler-Taub British journal of anaesthesia 108 (1), 134-139, 2012 | 13 | 2012 |
| Most robust BIBDs JP Morgan, V Parvu Statistica Sinica, 689-707, 2008 | 11 | 2008 |
| Risk stratification of HPV-positive results using extended genotyping and cytology: data from the baseline phase of the Onclarity trial MH Stoler, V Parvu, K Yanson, J Andrews, L Vaughan Gynecologic Oncology 174, 68-75, 2023 | 9 | 2023 |
| Large-scale SARS-CoV-2 antigen testing with real-world specimens A Parikh, L Cooper, D Frogel, K Le Benger, CK Cooper, V Parvu Frontiers in Public Health 10, 836328, 2022 | 9 | 2022 |
| Optimal row–column design for three treatments JP Morgan, V Parvu Journal of statistical planning and inference 137 (4), 1474-1487, 2007 | 9 | 2007 |
| E-optimal designs for three treatments V Parvu, JP Morgan Journal of statistical planning and inference 138 (3), 642-653, 2008 | 7 | 2008 |
| Detection of high-grade cervical neoplasia using extended genotyping: Performance data from the longitudinal phase of the Onclarity trial MH Stoler, TC Wright Jr, V Parvu, K Yanson, CK Cooper, JA Andrews Gynecologic Oncology 170, 143-152, 2023 | 6 | 2023 |